Zilganersen is a medicine used to treat Alexander disease, a rare genetic disease that damages the brain and spinal cord. It is given as an injection into the fluid around the spine. It works by lowering the amount of a harmful protein called GFAP that builds up in the brain.
Every report comes from a Lived member, sent anonymously.
Have you tried Zanvastro (Zilganersen) for Alexander Disease?
Zilganersen, sold as Zanvastro, is a prescription medicine for Alexander disease in children and adults. It was approved in the United States in 2026. Unlike the supportive treatments used until now, it targets the protein that drives the disease. Alexander disease is a rare genetic disorder of the brain and spinal cord. It belongs to the leukodystrophies, conditions that damage white matter, the insulated wiring that carries signals between nerve cells. Most cases start in infancy, with seizures, an enlarged head, stiff limbs and delayed development. Forms that start later in childhood or in adulthood more often cause problems with speech, swallowing, balance and walking. Zilganersen does not replace the physical, speech and feeding therapies and symptom treatments that remain the core of everyday care.
Alexander disease is caused by a change in the gene for GFAP (glial fibrillary acidic protein), a structural protein in astrocytes, the cells that support and nourish nerve cells. The altered protein builds up inside astrocytes and forms clumps that interfere with how these cells work, and the damage to white matter follows. Zilganersen is an antisense oligonucleotide, a short, lab-made strand of genetic material designed to match the message cells use to make GFAP. When it attaches to that message, the cell breaks the message down, so less GFAP is produced. The aim is to slow the buildup that drives the disease. It does not correct the gene itself, and it cannot undo damage that has already happened.
Zilganersen is given by lumbar puncture (spinal tap): a needle placed between the bones of the lower back delivers the medicine into the fluid around the spinal cord, so it can reach the brain directly. The dose is 50 mg every 3 months, given in a clinic or hospital by clinicians experienced with the procedure. The diluted volume depends on age, so infants receive a smaller volume of fluid than older children and adults. Before each injection, the team checks for anything that makes a lumbar puncture riskier. Sedation or local numbing medicine may be used, and imaging may guide the needle when the spine is hard to access. If a dose is missed, it is given as soon as possible, and the 3-month schedule restarts from that date.
In the main trial, the most common problems seen more often with zilganersen than in the control group were vomiting, back pain, cough, headache and post-lumbar puncture syndrome (a headache, often worse when sitting or standing, that can follow a spinal tap). Joint pain, sore throat and trouble swallowing were also more common. Many of these relate to the injection procedure itself. Zilganersen can cause aseptic meningitis, an inflammation of the membranes around the brain and spinal cord that is not caused by infection. In the trial one person had a serious episode that came back on later doses and was managed by pausing treatment and giving a steroid before each injection. Contact the care team promptly if fever, severe headache, a stiff neck, vomiting or unusual sensitivity to light develop. Routine spinal fluid tests can also show raised white blood cell counts without any symptoms, which the team watches over time.
No medicines are listed as off limits with zilganersen, and the label names no specific drug interactions. Because each dose needs a lumbar puncture, tell the team about blood thinners, bleeding problems or anything else that could make the procedure riskier, and share the full list of medicines and supplements. There are no human data on zilganersen in pregnancy or breastfeeding. Anyone who is pregnant, planning a pregnancy or breastfeeding should weigh the unknowns against the effects of the disease with the treating team.
Zilganersen is meant to slow the progression of Alexander disease, not to reverse it. Its approval rests on one small trial of 49 people aged 2 to 65. Among those 5 and older with walking problems, walking speed over about 14 months stayed roughly steady with treatment, while it fell by about a third in the control group. Children aged 2 to 4 showed a similar pattern on motor tests, but there were only seven of them. Only four infants under 2 were studied. How long the benefit lasts, and how much it varies between forms of the disease, is not yet known. Treatment means a clinic visit and spinal tap four times a year on an ongoing schedule, and headache or back soreness after a dose is common. There is no simple blood test that shows the medicine is working; in the trial, benefit was judged by walking and motor assessments over more than a year, so it can take months to judge how things are going. Specialist neurology care, therapies and support for daily living continue alongside the injections.
Last reviewed • Oct 2026
Educational content, not medical advice.
Share your experience taking Zanvastro (Zilganersen), what you've noticed, or ask the community a question.